 Alvotech NASDAQ: ALVO, a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today the initiation of a pharmacokinetic study for AVT05, a biosimilar candidate to Simponi and Simponi Aria golimumab. The study will assess the pharmacokinetics, safety, and tolerability of AVT05 compared to Simponi in healthy adult... The post Alvotech Initiates Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi and Si... 